A clinical trial carried out at the University of Liverpool has shown that a commonly used chemotherapy drug is equally effective as more expensive treatments for pancreatic cancer.
The drug, 5-fluorouralcil, has been shown to help prevent recurrence of the cancer in patients who have undergone a surgery.
Go deeper with GlobalData
Professor John Neoptolemos of the Institute of Translational Medicine said the study indicates that patients now have a backup drug in case standard chemotherapy fails.
“We’ve already launched a new trial investigating whether combining the two treatments could be even more effective and prolong life,” Neoptolemos said.
An estimated 7,800 people are diagnosed with pancreatic cancer in the UK every year. The five-year survival rate is 3%.
The trial took place in 159 centres in Australasia, Canada, Europe and Japan and involved 1,088 patients who had undergone pancreatic cancer surgery.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOne group were given standard chemotherapy drug gemcitabine, while the other had the less-expensive but widely available 5-fluorouracil.
